nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefuroxime—Skin disorder—Cisplatin—testicular cancer	0.00158	0.00158	CcSEcCtD
Cefuroxime—Hyperhidrosis—Cisplatin—testicular cancer	0.00157	0.00157	CcSEcCtD
Cefuroxime—Pruritus—Bleomycin—testicular cancer	0.00156	0.00156	CcSEcCtD
Cefuroxime—Chest pain—Etoposide—testicular cancer	0.00155	0.00155	CcSEcCtD
Cefuroxime—Eosinophilia—Methotrexate—testicular cancer	0.00155	0.00155	CcSEcCtD
Cefuroxime—Nausea—Vinblastine—testicular cancer	0.00155	0.00155	CcSEcCtD
Cefuroxime—Anorexia—Cisplatin—testicular cancer	0.00155	0.00155	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00154	0.00154	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00154	0.00154	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.00153	0.00153	CcSEcCtD
Cefuroxime—Hypersensitivity—Dactinomycin—testicular cancer	0.00152	0.00152	CcSEcCtD
Cefuroxime—Urticaria—Ifosfamide—testicular cancer	0.0015	0.0015	CcSEcCtD
Cefuroxime—Abdominal pain—Ifosfamide—testicular cancer	0.00149	0.00149	CcSEcCtD
Cefuroxime—Body temperature increased—Ifosfamide—testicular cancer	0.00149	0.00149	CcSEcCtD
Cefuroxime—Pancytopenia—Methotrexate—testicular cancer	0.00149	0.00149	CcSEcCtD
Cefuroxime—Anaphylactic shock—Etoposide—testicular cancer	0.00149	0.00149	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00148	0.00148	CcSEcCtD
Cefuroxime—Blood creatinine increased—Doxorubicin—testicular cancer	0.00147	0.00147	CcSEcCtD
Cefuroxime—Dysuria—Methotrexate—testicular cancer	0.00147	0.00147	CcSEcCtD
Cefuroxime—Neutropenia—Methotrexate—testicular cancer	0.00147	0.00147	CcSEcCtD
Cefuroxime—Thrombocytopenia—Etoposide—testicular cancer	0.00146	0.00146	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Methotrexate—testicular cancer	0.00146	0.00146	CcSEcCtD
Cefuroxime—Tachycardia—Etoposide—testicular cancer	0.00145	0.00145	CcSEcCtD
Cefuroxime—Eosinophilia—Epirubicin—testicular cancer	0.00145	0.00145	CcSEcCtD
Cefuroxime—Dyspnoea—Cisplatin—testicular cancer	0.00145	0.00145	CcSEcCtD
Cefuroxime—Skin disorder—Etoposide—testicular cancer	0.00145	0.00145	CcSEcCtD
Cefuroxime—Hyperhidrosis—Etoposide—testicular cancer	0.00144	0.00144	CcSEcCtD
Cefuroxime—Anorexia—Etoposide—testicular cancer	0.00142	0.00142	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Cefuroxime—Decreased appetite—Cisplatin—testicular cancer	0.00141	0.00141	CcSEcCtD
Cefuroxime—Bronchitis—Epirubicin—testicular cancer	0.00141	0.00141	CcSEcCtD
Cefuroxime—Diarrhoea—Dactinomycin—testicular cancer	0.00141	0.00141	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Cisplatin—testicular cancer	0.0014	0.0014	CcSEcCtD
Cefuroxime—Vomiting—Bleomycin—testicular cancer	0.0014	0.0014	CcSEcCtD
Cefuroxime—Infestation—Methotrexate—testicular cancer	0.0014	0.0014	CcSEcCtD
Cefuroxime—Infestation NOS—Methotrexate—testicular cancer	0.0014	0.0014	CcSEcCtD
Cefuroxime—Drowsiness—Methotrexate—testicular cancer	0.0014	0.0014	CcSEcCtD
Cefuroxime—Pancytopenia—Epirubicin—testicular cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Rash—Bleomycin—testicular cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Pain—Cisplatin—testicular cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Dermatitis—Bleomycin—testicular cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Hypersensitivity—Ifosfamide—testicular cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Renal failure—Methotrexate—testicular cancer	0.00137	0.00137	CcSEcCtD
Cefuroxime—Neutropenia—Epirubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Cefuroxime—Dysuria—Epirubicin—testicular cancer	0.00137	0.00137	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Epirubicin—testicular cancer	0.00136	0.00136	CcSEcCtD
Cefuroxime—Stomatitis—Methotrexate—testicular cancer	0.00136	0.00136	CcSEcCtD
Cefuroxime—Eosinophilia—Doxorubicin—testicular cancer	0.00134	0.00134	CcSEcCtD
Cefuroxime—Sweating—Methotrexate—testicular cancer	0.00134	0.00134	CcSEcCtD
Cefuroxime—Pruritus—Ifosfamide—testicular cancer	0.00133	0.00133	CcSEcCtD
Cefuroxime—Dyspnoea—Etoposide—testicular cancer	0.00133	0.00133	CcSEcCtD
Cefuroxime—Somnolence—Etoposide—testicular cancer	0.00132	0.00132	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Methotrexate—testicular cancer	0.00132	0.00132	CcSEcCtD
Cefuroxime—Nausea—Bleomycin—testicular cancer	0.00131	0.00131	CcSEcCtD
Cefuroxime—Infestation NOS—Epirubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Cefuroxime—Infestation—Epirubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Cefuroxime—Drowsiness—Epirubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Cefuroxime—Vomiting—Dactinomycin—testicular cancer	0.00131	0.00131	CcSEcCtD
Cefuroxime—Bronchitis—Doxorubicin—testicular cancer	0.00131	0.00131	CcSEcCtD
Cefuroxime—Agranulocytosis—Methotrexate—testicular cancer	0.0013	0.0013	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.0013	0.0013	CcSEcCtD
Cefuroxime—Rash—Dactinomycin—testicular cancer	0.0013	0.0013	CcSEcCtD
Cefuroxime—Decreased appetite—Etoposide—testicular cancer	0.00129	0.00129	CcSEcCtD
Cefuroxime—Diarrhoea—Ifosfamide—testicular cancer	0.00129	0.00129	CcSEcCtD
Cefuroxime—Pancytopenia—Doxorubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Cefuroxime—Renal failure—Epirubicin—testicular cancer	0.00129	0.00129	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Etoposide—testicular cancer	0.00129	0.00129	CcSEcCtD
Cefuroxime—Body temperature increased—Cisplatin—testicular cancer	0.00128	0.00128	CcSEcCtD
Cefuroxime—Stomatitis—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Cefuroxime—Jaundice—Epirubicin—testicular cancer	0.00128	0.00128	CcSEcCtD
Cefuroxime—Pain—Etoposide—testicular cancer	0.00127	0.00127	CcSEcCtD
Cefuroxime—Urinary tract infection—Epirubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Cefuroxime—Neutropenia—Doxorubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Cefuroxime—Dysuria—Doxorubicin—testicular cancer	0.00127	0.00127	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.00126	0.00126	CcSEcCtD
Cefuroxime—Haemoglobin—Methotrexate—testicular cancer	0.00126	0.00126	CcSEcCtD
Cefuroxime—Haemorrhage—Methotrexate—testicular cancer	0.00126	0.00126	CcSEcCtD
Cefuroxime—Hepatitis—Methotrexate—testicular cancer	0.00126	0.00126	CcSEcCtD
Cefuroxime—Sweating—Epirubicin—testicular cancer	0.00125	0.00125	CcSEcCtD
Cefuroxime—Dizziness—Ifosfamide—testicular cancer	0.00125	0.00125	CcSEcCtD
Cefuroxime—Urinary tract disorder—Methotrexate—testicular cancer	0.00124	0.00124	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Epirubicin—testicular cancer	0.00124	0.00124	CcSEcCtD
Cefuroxime—Urethral disorder—Methotrexate—testicular cancer	0.00123	0.00123	CcSEcCtD
Cefuroxime—Sinusitis—Epirubicin—testicular cancer	0.00123	0.00123	CcSEcCtD
Cefuroxime—Nausea—Dactinomycin—testicular cancer	0.00122	0.00122	CcSEcCtD
Cefuroxime—Agranulocytosis—Epirubicin—testicular cancer	0.00122	0.00122	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Etoposide—testicular cancer	0.00122	0.00122	CcSEcCtD
Cefuroxime—Infestation—Doxorubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Cefuroxime—Drowsiness—Doxorubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Cefuroxime—Infestation NOS—Doxorubicin—testicular cancer	0.00121	0.00121	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.0012	0.0012	CcSEcCtD
Cefuroxime—Vomiting—Ifosfamide—testicular cancer	0.0012	0.0012	CcSEcCtD
Cefuroxime—Hypersensitivity—Cisplatin—testicular cancer	0.0012	0.0012	CcSEcCtD
Cefuroxime—Renal failure—Doxorubicin—testicular cancer	0.00119	0.00119	CcSEcCtD
Cefuroxime—Rash—Ifosfamide—testicular cancer	0.00119	0.00119	CcSEcCtD
Cefuroxime—Dermatitis—Ifosfamide—testicular cancer	0.00119	0.00119	CcSEcCtD
Cefuroxime—Erythema multiforme—Methotrexate—testicular cancer	0.00119	0.00119	CcSEcCtD
Cefuroxime—Urticaria—Etoposide—testicular cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Haemoglobin—Epirubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Stomatitis—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Jaundice—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Abdominal pain—Etoposide—testicular cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Body temperature increased—Etoposide—testicular cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Urinary tract infection—Doxorubicin—testicular cancer	0.00118	0.00118	CcSEcCtD
Cefuroxime—Hepatitis—Epirubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Cefuroxime—Haemorrhage—Epirubicin—testicular cancer	0.00117	0.00117	CcSEcCtD
Cefuroxime—Sweating—Doxorubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Cefuroxime—Urinary tract disorder—Epirubicin—testicular cancer	0.00116	0.00116	CcSEcCtD
Cefuroxime—Urethral disorder—Epirubicin—testicular cancer	0.00115	0.00115	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Cefuroxime—Angiopathy—Methotrexate—testicular cancer	0.00114	0.00114	CcSEcCtD
Cefuroxime—Sinusitis—Doxorubicin—testicular cancer	0.00114	0.00114	CcSEcCtD
Cefuroxime—Immune system disorder—Methotrexate—testicular cancer	0.00113	0.00113	CcSEcCtD
Cefuroxime—Agranulocytosis—Doxorubicin—testicular cancer	0.00113	0.00113	CcSEcCtD
Cefuroxime—Chills—Methotrexate—testicular cancer	0.00113	0.00113	CcSEcCtD
Cefuroxime—Nausea—Ifosfamide—testicular cancer	0.00112	0.00112	CcSEcCtD
Cefuroxime—Diarrhoea—Cisplatin—testicular cancer	0.00111	0.00111	CcSEcCtD
Cefuroxime—Erythema multiforme—Epirubicin—testicular cancer	0.00111	0.00111	CcSEcCtD
Cefuroxime—Hypersensitivity—Etoposide—testicular cancer	0.0011	0.0011	CcSEcCtD
Cefuroxime—Erythema—Methotrexate—testicular cancer	0.00109	0.00109	CcSEcCtD
Cefuroxime—Haemoglobin—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Cefuroxime—Hepatitis—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Cefuroxime—Haemorrhage—Doxorubicin—testicular cancer	0.00109	0.00109	CcSEcCtD
Cefuroxime—Urinary tract disorder—Doxorubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Cefuroxime—Angiopathy—Epirubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Cefuroxime—Urethral disorder—Doxorubicin—testicular cancer	0.00107	0.00107	CcSEcCtD
Cefuroxime—Immune system disorder—Epirubicin—testicular cancer	0.00106	0.00106	CcSEcCtD
Cefuroxime—Chills—Epirubicin—testicular cancer	0.00105	0.00105	CcSEcCtD
Cefuroxime—Pruritus—Etoposide—testicular cancer	0.00105	0.00105	CcSEcCtD
Cefuroxime—Vomiting—Cisplatin—testicular cancer	0.00103	0.00103	CcSEcCtD
Cefuroxime—Erythema multiforme—Doxorubicin—testicular cancer	0.00103	0.00103	CcSEcCtD
Cefuroxime—Rash—Cisplatin—testicular cancer	0.00102	0.00102	CcSEcCtD
Cefuroxime—Dermatitis—Cisplatin—testicular cancer	0.00102	0.00102	CcSEcCtD
Cefuroxime—Erythema—Epirubicin—testicular cancer	0.00102	0.00102	CcSEcCtD
Cefuroxime—Diarrhoea—Etoposide—testicular cancer	0.00102	0.00102	CcSEcCtD
Cefuroxime—Flatulence—Epirubicin—testicular cancer	0.00101	0.00101	CcSEcCtD
Cefuroxime—Angiopathy—Doxorubicin—testicular cancer	0.000986	0.000986	CcSEcCtD
Cefuroxime—Dizziness—Etoposide—testicular cancer	0.000984	0.000984	CcSEcCtD
Cefuroxime—Muscle spasms—Epirubicin—testicular cancer	0.000983	0.000983	CcSEcCtD
Cefuroxime—Immune system disorder—Doxorubicin—testicular cancer	0.000982	0.000982	CcSEcCtD
Cefuroxime—Leukopenia—Methotrexate—testicular cancer	0.000978	0.000978	CcSEcCtD
Cefuroxime—Chills—Doxorubicin—testicular cancer	0.000975	0.000975	CcSEcCtD
Cefuroxime—Nausea—Cisplatin—testicular cancer	0.000965	0.000965	CcSEcCtD
Cefuroxime—Cough—Methotrexate—testicular cancer	0.000953	0.000953	CcSEcCtD
Cefuroxime—Convulsion—Methotrexate—testicular cancer	0.000947	0.000947	CcSEcCtD
Cefuroxime—Vomiting—Etoposide—testicular cancer	0.000947	0.000947	CcSEcCtD
Cefuroxime—Erythema—Doxorubicin—testicular cancer	0.000946	0.000946	CcSEcCtD
Cefuroxime—Agitation—Epirubicin—testicular cancer	0.00094	0.00094	CcSEcCtD
Cefuroxime—Rash—Etoposide—testicular cancer	0.000939	0.000939	CcSEcCtD
Cefuroxime—Dermatitis—Etoposide—testicular cancer	0.000938	0.000938	CcSEcCtD
Cefuroxime—Headache—Etoposide—testicular cancer	0.000933	0.000933	CcSEcCtD
Cefuroxime—Flatulence—Doxorubicin—testicular cancer	0.000932	0.000932	CcSEcCtD
Cefuroxime—Chest pain—Methotrexate—testicular cancer	0.00093	0.00093	CcSEcCtD
Cefuroxime—Arthralgia—Methotrexate—testicular cancer	0.00093	0.00093	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000924	0.000924	CcSEcCtD
Cefuroxime—Leukopenia—Epirubicin—testicular cancer	0.000915	0.000915	CcSEcCtD
Cefuroxime—Muscle spasms—Doxorubicin—testicular cancer	0.00091	0.00091	CcSEcCtD
Cefuroxime—Palpitations—Epirubicin—testicular cancer	0.000904	0.000904	CcSEcCtD
Cefuroxime—Cough—Epirubicin—testicular cancer	0.000892	0.000892	CcSEcCtD
Cefuroxime—Anaphylactic shock—Methotrexate—testicular cancer	0.000892	0.000892	CcSEcCtD
Cefuroxime—Convulsion—Epirubicin—testicular cancer	0.000886	0.000886	CcSEcCtD
Cefuroxime—Nausea—Etoposide—testicular cancer	0.000884	0.000884	CcSEcCtD
Cefuroxime—Thrombocytopenia—Methotrexate—testicular cancer	0.000873	0.000873	CcSEcCtD
Cefuroxime—Arthralgia—Epirubicin—testicular cancer	0.00087	0.00087	CcSEcCtD
Cefuroxime—Chest pain—Epirubicin—testicular cancer	0.00087	0.00087	CcSEcCtD
Cefuroxime—Agitation—Doxorubicin—testicular cancer	0.000869	0.000869	CcSEcCtD
Cefuroxime—Skin disorder—Methotrexate—testicular cancer	0.000866	0.000866	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000864	0.000864	CcSEcCtD
Cefuroxime—Hyperhidrosis—Methotrexate—testicular cancer	0.000862	0.000862	CcSEcCtD
Cefuroxime—Anorexia—Methotrexate—testicular cancer	0.00085	0.00085	CcSEcCtD
Cefuroxime—Leukopenia—Doxorubicin—testicular cancer	0.000847	0.000847	CcSEcCtD
Cefuroxime—Palpitations—Doxorubicin—testicular cancer	0.000836	0.000836	CcSEcCtD
Cefuroxime—Anaphylactic shock—Epirubicin—testicular cancer	0.000834	0.000834	CcSEcCtD
Cefuroxime—Cough—Doxorubicin—testicular cancer	0.000826	0.000826	CcSEcCtD
Cefuroxime—Convulsion—Doxorubicin—testicular cancer	0.00082	0.00082	CcSEcCtD
Cefuroxime—Thrombocytopenia—Epirubicin—testicular cancer	0.000817	0.000817	CcSEcCtD
Cefuroxime—Tachycardia—Epirubicin—testicular cancer	0.000814	0.000814	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000812	0.000812	CcSEcCtD
Cefuroxime—Skin disorder—Epirubicin—testicular cancer	0.000811	0.000811	CcSEcCtD
Cefuroxime—Hyperhidrosis—Epirubicin—testicular cancer	0.000807	0.000807	CcSEcCtD
Cefuroxime—Chest pain—Doxorubicin—testicular cancer	0.000805	0.000805	CcSEcCtD
Cefuroxime—Arthralgia—Doxorubicin—testicular cancer	0.000805	0.000805	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.0008	0.0008	CcSEcCtD
Cefuroxime—Anorexia—Epirubicin—testicular cancer	0.000795	0.000795	CcSEcCtD
Cefuroxime—Dyspnoea—Methotrexate—testicular cancer	0.000795	0.000795	CcSEcCtD
Cefuroxime—Somnolence—Methotrexate—testicular cancer	0.000793	0.000793	CcSEcCtD
Cefuroxime—Dyspepsia—Methotrexate—testicular cancer	0.000785	0.000785	CcSEcCtD
Cefuroxime—Decreased appetite—Methotrexate—testicular cancer	0.000775	0.000775	CcSEcCtD
Cefuroxime—Anaphylactic shock—Doxorubicin—testicular cancer	0.000772	0.000772	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Methotrexate—testicular cancer	0.00077	0.00077	CcSEcCtD
Cefuroxime—Pain—Methotrexate—testicular cancer	0.000763	0.000763	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.00076	0.00076	CcSEcCtD
Cefuroxime—Thrombocytopenia—Doxorubicin—testicular cancer	0.000756	0.000756	CcSEcCtD
Cefuroxime—Tachycardia—Doxorubicin—testicular cancer	0.000754	0.000754	CcSEcCtD
Cefuroxime—Skin disorder—Doxorubicin—testicular cancer	0.00075	0.00075	CcSEcCtD
Cefuroxime—Hyperhidrosis—Doxorubicin—testicular cancer	0.000746	0.000746	CcSEcCtD
Cefuroxime—Dyspnoea—Epirubicin—testicular cancer	0.000744	0.000744	CcSEcCtD
Cefuroxime—Somnolence—Epirubicin—testicular cancer	0.000742	0.000742	CcSEcCtD
Cefuroxime—Anorexia—Doxorubicin—testicular cancer	0.000736	0.000736	CcSEcCtD
Cefuroxime—Dyspepsia—Epirubicin—testicular cancer	0.000735	0.000735	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Methotrexate—testicular cancer	0.000729	0.000729	CcSEcCtD
Cefuroxime—Decreased appetite—Epirubicin—testicular cancer	0.000725	0.000725	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00072	0.00072	CcSEcCtD
Cefuroxime—Pain—Epirubicin—testicular cancer	0.000714	0.000714	CcSEcCtD
Cefuroxime—Urticaria—Methotrexate—testicular cancer	0.000708	0.000708	CcSEcCtD
Cefuroxime—Abdominal pain—Methotrexate—testicular cancer	0.000705	0.000705	CcSEcCtD
Cefuroxime—Body temperature increased—Methotrexate—testicular cancer	0.000705	0.000705	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000703	0.000703	CcSEcCtD
Cefuroxime—Dyspnoea—Doxorubicin—testicular cancer	0.000688	0.000688	CcSEcCtD
Cefuroxime—Somnolence—Doxorubicin—testicular cancer	0.000686	0.000686	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Epirubicin—testicular cancer	0.000682	0.000682	CcSEcCtD
Cefuroxime—Dyspepsia—Doxorubicin—testicular cancer	0.00068	0.00068	CcSEcCtD
Cefuroxime—Decreased appetite—Doxorubicin—testicular cancer	0.000671	0.000671	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000667	0.000667	CcSEcCtD
Cefuroxime—Urticaria—Epirubicin—testicular cancer	0.000663	0.000663	CcSEcCtD
Cefuroxime—Pain—Doxorubicin—testicular cancer	0.00066	0.00066	CcSEcCtD
Cefuroxime—Abdominal pain—Epirubicin—testicular cancer	0.00066	0.00066	CcSEcCtD
Cefuroxime—Body temperature increased—Epirubicin—testicular cancer	0.00066	0.00066	CcSEcCtD
Cefuroxime—Hypersensitivity—Methotrexate—testicular cancer	0.000657	0.000657	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000631	0.000631	CcSEcCtD
Cefuroxime—Pruritus—Methotrexate—testicular cancer	0.000631	0.000631	CcSEcCtD
Cefuroxime—Hypersensitivity—Epirubicin—testicular cancer	0.000615	0.000615	CcSEcCtD
Cefuroxime—Urticaria—Doxorubicin—testicular cancer	0.000613	0.000613	CcSEcCtD
Cefuroxime—Abdominal pain—Doxorubicin—testicular cancer	0.00061	0.00061	CcSEcCtD
Cefuroxime—Body temperature increased—Doxorubicin—testicular cancer	0.00061	0.00061	CcSEcCtD
Cefuroxime—Diarrhoea—Methotrexate—testicular cancer	0.00061	0.00061	CcSEcCtD
Cefuroxime—Pruritus—Epirubicin—testicular cancer	0.00059	0.00059	CcSEcCtD
Cefuroxime—Dizziness—Methotrexate—testicular cancer	0.00059	0.00059	CcSEcCtD
Cefuroxime—Diarrhoea—Epirubicin—testicular cancer	0.000571	0.000571	CcSEcCtD
Cefuroxime—Hypersensitivity—Doxorubicin—testicular cancer	0.000569	0.000569	CcSEcCtD
Cefuroxime—Vomiting—Methotrexate—testicular cancer	0.000567	0.000567	CcSEcCtD
Cefuroxime—Rash—Methotrexate—testicular cancer	0.000562	0.000562	CcSEcCtD
Cefuroxime—Dermatitis—Methotrexate—testicular cancer	0.000562	0.000562	CcSEcCtD
Cefuroxime—Headache—Methotrexate—testicular cancer	0.000559	0.000559	CcSEcCtD
Cefuroxime—Dizziness—Epirubicin—testicular cancer	0.000552	0.000552	CcSEcCtD
Cefuroxime—Pruritus—Doxorubicin—testicular cancer	0.000546	0.000546	CcSEcCtD
Cefuroxime—Vomiting—Epirubicin—testicular cancer	0.000531	0.000531	CcSEcCtD
Cefuroxime—Nausea—Methotrexate—testicular cancer	0.00053	0.00053	CcSEcCtD
Cefuroxime—Diarrhoea—Doxorubicin—testicular cancer	0.000528	0.000528	CcSEcCtD
Cefuroxime—Rash—Epirubicin—testicular cancer	0.000526	0.000526	CcSEcCtD
Cefuroxime—Dermatitis—Epirubicin—testicular cancer	0.000526	0.000526	CcSEcCtD
Cefuroxime—Headache—Epirubicin—testicular cancer	0.000523	0.000523	CcSEcCtD
Cefuroxime—Dizziness—Doxorubicin—testicular cancer	0.000511	0.000511	CcSEcCtD
Cefuroxime—Nausea—Epirubicin—testicular cancer	0.000496	0.000496	CcSEcCtD
Cefuroxime—Vomiting—Doxorubicin—testicular cancer	0.000491	0.000491	CcSEcCtD
Cefuroxime—Rash—Doxorubicin—testicular cancer	0.000487	0.000487	CcSEcCtD
Cefuroxime—Dermatitis—Doxorubicin—testicular cancer	0.000486	0.000486	CcSEcCtD
Cefuroxime—Headache—Doxorubicin—testicular cancer	0.000484	0.000484	CcSEcCtD
Cefuroxime—Nausea—Doxorubicin—testicular cancer	0.000459	0.000459	CcSEcCtD
